Development of hematopoietic stem cell based gene therapy for HIV-1 infection: Considerations for proof of concept studies and translation to standard medical practice

Viruses

Volumn 5, Issue 11, 2013, Pages 2898-2919

  DiGiusto, David L ^a   Stan, Rodica ^a   Krishnan, Amrita ^b   Li, Haitang ^a   Rossi, John J ^a   Zaia, John A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Department of Hematology and Hematopoietic Cell Transplantation City of Hope ^*  (United States)

Author keywords

Gene therapy; HIV 1; Non ablative conditioning; Stem cells; Transplantation

Indexed keywords

ANTIRETROVIRUS AGENT; CARMUSTINE; FLUDARABINE; LENTIVIRUS VECTOR; PLACEBO; RIBOZYME; RITONAVIR; RITUXIMAB; SHORT HAIRPIN RNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG COST; ENZYME REPLACEMENT; ERYTHROPOIESIS; HEALTH CARE COST; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE STATUS; INTRON; LOW DRUG DOSE; LYMPHOPOIESIS; MAJOR CLINICAL STUDY; METACHROMATIC LEUKODYSTROPHY; MOUSE; MUCOSA INFLAMMATION; MUTATIONAL ANALYSIS; MYELOABLATIVE CONDITIONING; MYELOPOIESIS; NEUTROPENIA; NONHUMAN; PROGENY; PROMOTER REGION; TREATMENT INDICATION; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; WISKOTT ALDRICH SYNDROME;

ADOLESCENT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84888150047     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v5112898     Document Type: Article

References (81)

1. World Health Organization. Global HIV/AIDS response-epidemic update and health sector progress towards universal access: Progress report 2011. Available online: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf (accessed on 20 November 2013).
2. Chun, T.W.;Stuyver, L.;Mizell, S.B.;Ehler, L.A.;Mican, J.A.;Baseler, M.;Lloyd, A.L.;Nowak, M.A.;Fauci, A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U S A 1997, 94, 13193-13197.
3. Finzi, D.;Blankson, J.;Siliciano, J.D.;Margolick, J.B.;Chadwick, K.;Pierson, T.;Smith, K.;Lisziewicz, J.;Lori, F.;Flexner, C.;et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5, 512-517.
4. Finzi, D.;Hermankova, M.;Pierson, T.;Carruth, L.M.;Buck, C.;Chaisson, R.E.;Quinn, T.C.;Chadwick, K.;Margolick, J.;Brookmeyer, R.;et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278, 1295-1300.
5. Wong, J.K.;Hezareh, M.;Gunthard, H.F.;Havlir, D.V.;Ignacio, C.C.;Spina, C.A.;Richman, D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278, 1291-1295.
6. Calza, L. Renal toxicity associated with antiretroviral therapy. HIV Clin. Trials 2012, 13, 189-211.
7. Domingo, P.;Estrada, V.;Lopez-Aldeguer, J.;Villaroya, F.;Martinez, E. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev. 2012, 14, 112-123.
8. Hester, E.K. HIV medications: An update and review of metabolic complications. Nutr. Clin. Pract. 2012, 27, 51-64.
9. Jones, M.;Nunez, M. Liver toxicity of antiretroviral drugs. Semin. Liver Dis. 2012, 32, 167-176.
10. Lipshultz, S.E.;Mas, C.M.;Henkel, J.M.;Franco, V.I.;Fisher, S.D.;Miller, T.L. HAART to heart: Highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev. Anti-Infect. Ther. 2012, 10, 661-674.
11. Hutter, G.;Nowak, D.;Mossner, M.;Ganepola, S.;Mussig, A.;Allers, K.;Schneider, T.;Hofmann, J.;Kucherer, C.;Blau, O.;et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360, 692-698.
12. Allers, K.;Hutter, G.;Hofmann, J.;Loddenkemper, C.;Rieger, K.;Thiel, E.;Schneider, T. Evidence for the cure of HIV infection by CCR5delta32/delta32 stem cell transplantation. Blood 2011, 117, 2791-2799.
13. Yukl, S.A.;Boritz, E.;Busch, M.;Bentsen, C.;Chun, T.W.;Douek, D.;Eisele, E.;Haase, A.;Ho, Y.C.;Hutter, G.;et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog. 2013, 9, e1003347.
14. Henrich, T.J.;Hu, Z.;Li, J.Z.;Sciaranghella, G.;Busch, M.P.;Keating, S.M.;Gallien, S.;Lin, N.H.;Giguel, F.F.;Lavoie, L.;et al. Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 2013, 207, 1694-1702.
15. Hutter, G.;Zaia, J.A. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: The experiences of more than 25 years. Clin. Exp. Immunol. 2011, 163, 284-295.
16. Burnett, J.C.;Zaia, J.A.;Rossi, J.J. Creating genetic resistance to HIV. Curr. Opin. Immunol. 2012, 24, 625-632.
17. Holt, N.;Wang, J.;Kim, K.;Friedman, G.;Wang, X.;Taupin, V.;Crooks, G.M.;Kohn, D.B.;Gregory, P.D.;Holmes, M.C.;et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 2010, 28, 839-847.
18. Hur, E.M.;Patel, S.N.;Shimizu, S.;Rao, D.S.;Gnanapragasam, P.N.;An, D.S.;Yang, L.;Baltimore, D. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012, 120, 4571-4582.
19. Joseph, A.;Zheng, J.H.;Chen, K.;Dutta, M.;Chen, C.;Stiegler, G.;Kunert, R.;Follenzi, A.;Goldstein, H. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J. Virol. 2010, 84, 6645-6653.
20. Ringpis, G.-E.E.;Shimizu, S.;Arokium, H.;Camba-Colón, J.;Carroll, M.V.;Cortado, R.;Xie, Y.;Kim, P.Y.;Sahakyan, A.;Lowe, E.L.;et al. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One 2012, 7, e53492.
21. Vatakis, D.N.;Bristol, G.C.;Kim, S.G.;Levin, B.;Liu, W.;Radu, C.G.;Kitchen, S.G.;Zack, J.A. Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J. Vis. Exp. 2012, (70), e4181. doi:10.3791/4181.
22. Kohn, D.B.;Bauer, G.;Rice, C.R.;Rothschild, J.C.;Carbonaro, D.A.;Valdez, P.;Hao, Q.;Zhou, C.;Bahner, I.;Kearns, K.;et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999, 94, 368-371.
23. Podsakoff, G.M.;Engel, B.C.;Carbonaro, D.A.;Choi, C.;Smogorzewska, E.M.;Bauer, G.;Selander, D.;Csik, S.;Wilson, K.;Betts, M.R.;et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol. Ther. 2005, 12, 77-86.
24. Amado, R.G.;Mitsuyasu, R.T.;Rosenblatt, J.D.;Ngok, F.K.;Bakker, A.;Cole, S.;Chorn, N.;Lin, L.S.;Bristol, G.;Boyd, M.P.;et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. 2004, 15, 251-262.
25. Mitsuyasu, R.T.;Merigan, T.C.;Carr, A.;Zack, J.A.;Winters, M.A.;Workman, C.;Bloch, M.;Lalezari, J.;Becker, S.;Thornton, L.;et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat. Med. 2009, 15, 285-292.
26. DiGiusto, D.L.;Krishnan, A.;Li, L.;Li, H.;Li, S.;Rao, A.;Mi, S.;Yam, P.;Stinson, S.;Kalos, M.;et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010, 2, 1-8.
27. Li, M.J.;Kim, J.;Li, S.;Zaia, J.;Yee, J.K.;Anderson, J.;Akkina, R.;Rossi, J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12, 900-909.
28. Ustek, D.;Sirma, S.;Gumus, E.;Arikan, M.;Cakiris, A.;Abaci, N.;Mathew, J.;Emrence, Z.;Azakli, H.;Cosan, F.;et al. A genome-wide analysis of lentivector integration sites using targeted sequence capture and next generation sequencing technology. Infect. Genet. Evol. 2012, 12, 1349-1354.
29. An, D.S.;Qin, F.X.;Auyeung, V.C.;Mao, S.H.;Kung, S.K.;Baltimore, D.;Chen, I.S. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther. 2006, 14, 494-504.
30. Chung, J.;Zhang, J.;Li, H.;Ouellet, D.L.;DiGiusto, D.L.;Rossi, J.J. Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy. Hum. Gene Ther. 2012, 23, 1200-1208.
31. Davis, B.M.;Roth, J.C.;Liu, L.;Xu-Welliver, M.;Pegg, A.E.;Gerson, S.L. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: Implications for drug resistance gene therapy. Hum. Gene Ther. 1999, 10, 2769-2778.
32. Beard, B.C.;Trobridge, G.D.;Ironside, C.;McCune, J.S.;Adair, J.E.;Kiem, H.P. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin. Invest. 2010, 120, 2345-2354.
33. Chinnasamy, D.;Fairbairn, L.J.;Neuenfeldt, J.;Treisman, J.S.;Hanson, J.P., Jr.;Margison, G.P.;Chinnasamy, N. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum. Gene Ther. 2004, 15, 758-769.
34. Gori, J.L.;Beard, B.C.;Ironside, C.;Karponi, G.;Kiem, H.P. In vivo selection of autologous mgmt gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. Cancer Gene Ther. 2012, 19, 523-529.
35. Jansen, M.;Sorg, U.R.;Ragg, S.;Flasshove, M.;Seeber, S.;Williams, D.A.;Moritz, T. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther. 2002, 9, 737-746.
36. Neff, T.;Beard, B.C.;Peterson, L.J.;Anandakumar, P.;Thompson, J.;Kiem, H.P. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005, 105, 997-1002.
37. Younan, P.M.;Polacino, P.;Kowalski, J.P.;Peterson, C.W.;Maurice, N.J.;Williams, N.P.;Ho, O.;Trobridge, G.D.;Von Laer, D.;Prlic, M.;et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 2013, 122, 179-187.
38. Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making. Draft PDUFA V Implementation Plan-February 2013;Fiscal Years 2013-2017. Available online: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrug UserFee/UCM329758.pdf (accessed on 20 November 2013).
39. Coplan, P.M.;Noel, R.A.;Levitan, B.S.;Ferguson, J.;Mussen, F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin. Pharmacol. Ther. 2011, 89, 312-315.
40. Food and Drug Administration. Public meeting on HIV patient-focused drug development and HIV cure research. 2013. Available online: http://www.fda.gov/ForIndustry/UserFees/ PrescriptionDrugUserFee/ucm348598.htm (accessed on 20 November 2013).
41. National Institutes of Health. AIDSinfo. Federally approved HIV/AIDS medical practice guidelines. 2013. Available online: http://aidsinfo.nih.gov/guidelines (accessed on 20 November 2013).
42. Lewden, C.;Chene, G.;Morlat, P.;Raffi, F.;Dupon, M.;Dellamonica, P.;Pellegrin, J.L.;Katlama, C.;Dabis, F.;Leport, C.;et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 2007, 46, 72-77.
43. Engsig, F.N.;Gerstoft, J.;Kronborg, G.;Larsen, C.S.;Pedersen, G.;Roge, B.;Jensen, J.;Nielsen, L.N.;Obel, N. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: A cohort study. BMC Infect. Dis. 2010, 10, 318.
44. Gaardbo, J.C.;Hartling, H.J.;Gerstoft, J.;Nielsen, S.D. Incomplete immune recovery in HIV infection: Mechanisms, relevance for clinical care, and possible solutions. Clin. Dev. Immunol. 2012, 2012, 670957.
45. Piketty, C.;Weiss, L.;Thomas, F.;Mohamed, A.S.;Belec, L.;Kazatchkine, M.D. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J. Infect. Dis. 2001, 183, 1328-1335.
46. Re, A.;Cattaneo, C.;Skert, C.;Balsalobre, P.;Michieli, M.;Bower, M.;Ferreri, A.J.;Hentrich, M.;Ribera, J.M.;Allione, B.;et al. Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica 2013, 98, 1762-1768.
47. Krishnan, A.;Bhatia, S.;Slovak, M.L.;Arber, D.A.;Niland, J.C.;Nademanee, A.;Fung, H.;Bhatia, R.;Kashyap, A.;Molina, A.;et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000, 95, 1588-1593.
48. Agarwal, D.;Chakravarty, J.;Chaube, L.;Rai, M.;Agrawal, N.R.;Sundar, S. High incidence of zidovudine induced anaemia in HIV infected patients in Eastern India. Indian J. Med. Res. 2010, 132, 386-389.
49. Costantini, A.;Giuliodoro, S.;Mancini, S.;Butini, L.;Regnery, C.M.;Silvestri, G.;Greco, F.;Leoni, P.;Montroni, M. Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replication. AIDS 2006, 20, 1713-1720.
50. Isgro, A.;Leti, W.;De Santis, W.;Marziali, M.;Esposito, A.;Fimiani, C.;Luzi, G.;Pinti, M.;Cossarizza, A.;Aiuti, F.;et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin. Infect. Dis. 2008, 46, 1902-1910.
51. Thiebot, H.;Louache, F.;Vaslin, B.;de Revel, T.;Neildez, O.;Larghero, J.;Vainchenker, W.;Dormont, D.;Le Grand, R. Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection. J. Virol. 2001, 75, 11594-11602.
52. Costantini, A.;Giuliodoro, S.;Butini, L.;Silvestri, G.;Leoni, P.;Montroni, M. Abnormalities of erythropoiesis during HIV-1 disease: A longitudinal analysis. J. Acquir. Immune Defic. Syndr. 2009, 52, 70-74.
53. Costantini, A.;Giuliodoro, S.;Butini, L.;Silvestri, G.;Leoni, P.;Montroni, M. HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy. Curr. HIV Res. 2010, 8, 336-339.
54. Sauce, D.;Larsen, M.;Fastenackels, S.;Pauchard, M.;Ait-Mohand, H.;Schneider, L.;Guihot, A.;Boufassa, F.;Zaunders, J.;Iguertsira, M., et al., HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011, 117, 5142-5151.
55. Krishnan, A. HIV-infected patients. Biol. Blood Marrow Transplant 2009, 15, 142-145.
56. Krishnan, A.;Molina, A.;Zaia, J.;Smith, D.;Vasquez, D.;Kogut, N.;Falk, P.M.;Rosenthal, J.;Alvarnas, J.;Forman, S.J. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005, 105, 874-878.
57. Schooley, R.T.;Mladenovic, J.;Sevin, A.;Chiu, S.;Miles, S.A.;Pomerantz, R.J.;Campbell, T.B.;Bell, D.;Ambruso, D.;Wong, R.;et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J. Infect. Dis. 2000, 181, 148-157.
58. Keating, G.M. Plerixafor: A review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011, 71, 1623-1647.
59. McNamara, L.A.;Ganesh, J.A.;Collins, K.L. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. J. Virol. 2012, 86, 9337-9350.
60. Nixon, C.C.;Vatakis, D.N.;Reichelderfer, S.N.;Dixit, D.;Kim, S.G.;Uittenbogaart, C.H.;Zack, J.A. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013, 122, 2195-2204.
61. Onafuwa-Nuga, A.;McNamara, L.A.;Collins, K.L. Towards a cure for HIV: The identification and characterization of HIV reservoirs in optimally treated people. Cell Res. 2010, 20, 1185-1187.
62. Eisele, E.;Siliciano, R.F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012, 37, 377-388.
63. McNamara, L.A.;Onafuwa-Nuga, A.;Sebastian, N.T.;Riddell, J.T.;Bixby, D.;Collins, K.L. CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J. Infect. Dis. 2013, 207, 1807-1816.
64. Sachdeva, M.;Fischl, M.A.;Pahwa, R.;Sachdeva, N.;Pahwa, S. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr. 2010, 54, 447-454.
65. Biffi, A.;Montini, E.;Lorioli, L.;Cesani, M.;Fumagalli, F.;Plati, T.;Baldoli, C.;Martino, S.;Calabria, A.;Canale, S.;et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013, 341, 1233158.
66. Aiuti, A.;Biasco, L.;Scaramuzza, S.;Ferrua, F.;Cicalese, M.P.;Baricordi, C.;Dionisio, F.;Calabria, A.;Giannelli, S.;Castiello, M.C.;et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341, 1233151.
67. Candotti, F.;Shaw, K.L.;Muul, L.;Carbonaro, D.;Sokolic, R.;Choi, C.;Schurman, S.H.;Garabedian, E.;Kesserwan, C.;Jagadeesh, G.J.;et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: Clinical comparison of retroviral vectors and treatment plans. Blood 2012, 120, 3635-3646.
68. Gutierrez-Aguirre, C.H.;Gomez-Almaguer, D.;Cantu-Rodriguez, O.G.;Gonzalez-Llano, O.;Jaime-Perez, J.C.;Herena-Perez, S.;Manzano, C.A.;Estrada-Gomez, R.;Gonzalez-Carrillo, M.L.;Ruiz-Arguelles, G.J. Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study. Bone Marrow Transplant. 2007, 40, 535-539.
69. Slavin, S.;Nagler, A.;Naparstek, E.;Kapelushnik, Y.;Aker, M.;Cividalli, G.;Varadi, G.;Kirschbaum, M.;Ackerstein, A.;Samuel, S.;et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91, 756-763.
70. Aiuti, A.;Cattaneo, F.;Galimberti, S.;Benninghoff, U.;Cassani, B.;Callegaro, L.;Scaramuzza, S.;Andolfi, G.;Mirolo, M.;Brigida, I.;et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360, 447-458.
71. Aiuti, A.;Slavin, S.;Aker, M.;Ficara, F.;Deola, S.;Mortellaro, A.;Morecki, S.;Andolfi, G.;Tabucchi, A.;Carlucci, F.;et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296, 2410-2413.
72. Kang, E.M.;Choi, U.;Theobald, N.;Linton, G.;Long Priel, D.A.;Kuhns, D.;Malech, H.L. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010, 115, 783-791.
73. Kang, H.J.;Bartholomae, C.C.;Paruzynski, A.;Arens, A.;Kim, S.;Yu, S.S.;Hong, Y.;Joo, C.W.;Yoon, N.K.;Rhim, J.W.;et al. Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial. Mol. Ther. 2011, 19, 2092-2101.
74. Ott, M.G.;Schmidt, M.;Schwarzwaelder, K.;Stein, S.;Siler, U.;Koehl, U.;Glimm, H.;Kuhlcke, K.;Schilz, A.;Kunkel, H.;et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006, 12, 401-409.
75. Lafeuillade, A. Potential strategies for an HIV infection cure. HIV Clin. Trials 2011, 12, 121-130.
76. Kiem, H.P.;Jerome, K.R.;Deeks, S.G.;McCune, J.M. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 2012, 10, 137-147.
77. Khera, N.;Zeliadt, S.B.;Lee, S.J. Economics of hematopoietic cell transplantation. Blood 2012, 120, 1545-1551.
78. Sloan, C.E.;Champenois, K.;Choisy, P.;Losina, E.;Walensky, R.P.;Schackman, B.R.;Ajana, F.;Melliez, H.;Paltiel, A.D.;Freedberg, K.A.;et al. Newer drugs and earlier treatment: Impact on lifetime cost of care for HIV-infected adults. AIDS 2012, 26, 45-56.
79. Walensky, R.P.;Sax, P.E.;Nakamura, Y.M.;Weinstein, M.C.;Pei, P.P.;Freedberg, K.A.;Paltiel, A.D.;Schackman, B.R. Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States. Ann. Intern Med. 2013, 158, 84-92.
80. Gabriel, R.;Eckenberg, R.;Paruzynski, A.;Bartholomae, C.C.;Nowrouzi, A.;Arens, A.;Howe, S.J.;Recchia, A.;Cattoglio, C.;Wang, W.;et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 2009, 15, 1431-1436.
81. Drmanac, R.;Drmanac, S.;Baier, J.;Chui, G.;Coleman, D.;Diaz, R.;Gietzen, D.;Hou, A.;Jin, H.;Ukrainczyk, T.;et al. DNA sequencing by hybridization with arrays of samples or probes. Methods Mol. Biol. 2001, 170, 173-179.